OOIR: Observatory of International Research

Papers

(The H4-Index of Molecular Therapy is 64. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
CANT1 lncRNA Triggers Efficient Therapeutic Efficacy by Correcting Aberrant lncing Cascade in Malignant Uveal Melanoma	289
Inhibition of NAD-GPx4 axis and MEK triggers ferroptosis to suppress pancreatic ductal adenocarcinoma	228
Asparagine endopeptidase protects podocytes in adriamycin-induced nephropathy by regulating actin dynamics through cleaving transgelin	210
Promotion or inhibition? This is a question in gene editing	205
Getting the host antiviral machinery back on track: Targeting viral suppressors of RNA interference	201
Ablation of dysmorphic neurons is a safe and effective treatment for focal cortical dysplasia II	185
Modulation of NLRP3 inflammasomes activation contributes to improved survival and function of mesenchymal stromal cell spheroids	182
Recent progress and future challenges in structure-based protein-protein interaction prediction	170
Engineering memory T cells as a platform for long-term enzyme replacement therapy in lysosomal storage disorders	161
Response to: DNA transposon mechanisms and pathways of genotoxicity	155
IL-1Ra gene transfer potentiates BMP2-mediated bone healing by redirecting osteogenesis toward endochondral ossification	147
Detection of chromosomal alteration after infusion of gene-edited allogeneic CAR T cells	146
A novel regulatory mechanism network mediated by lncRNA TUG1 that induces the impairment of spiral artery remodeling in preeclampsia	145
Durable immunogenicity, adaptation to emerging variants, and low-dose efficacy of an AAV-based COVID-19 vaccine platform in macaques	138
From cortex to medulla: Navigating the thymic landscape of T cell education	131
Enhanced fatty acid oxidation via SCD1 downregulation fuels cardiac reprogramming	129
Rescue of auditory function by a single administration of AAV-TMPRSS3 gene therapy in aged mice of human recessive deafness DFNB8	124
Reply to In vivo confusion over in vivo conversion	124
An engineered mitoCBE facilitates efficient mitochondrial DNA editing and modified mitochondrial transfer	124
Self-amplifying RNA vaccine protects mice against lethal Ebola virus infection	124
Development of a peptide drug restoring AMPK and adipose tissue functionality in cancer cachexia	122
RNAi mediated silencing of STAT3/PD-L1 in tumor-associated immune cells induces robust anti-tumor effects in immunotherapy resistant tumors	121
The ARDS microenvironment enhances MSC-induced repair via VEGF in experimental acute lung inflammation	118
α-L-iduronidase fused with humanized anti-human transferrin receptor antibody (lepunafusp alfa) for mucopolysaccharidosis type I: A phase 1/2 trial	115
miRNAs as neuro-oncologic therapeutics: A narrative review	112

Spike mutation resilient scFv76 antibody counteracts SARS-CoV-2 lung damage upon aerosol delivery	107
RNA interference targeting lipoprotein(a): A “big hit” against “little a”?	100
Ad-justing macrophages for cancer immunotherapy	100
Targeting EBV gp42 for nasopharyngeal carcinoma prevention	99
Preclinical lentiviral hematopoietic stem cell gene therapy corrects Pompe disease-related muscle and neurological manifestations	97
Safety concern of recombination between self-amplifying mRNA vaccines and viruses is mitigated in vivo	96
Reversion of metabolic dysfunction-associated steatohepatitis by skeletal muscle-directed FGF21 gene therapy	96
A highly stable human single-domain antibody-drug conjugate exhibits superior penetration and treatment of solid tumors	95
The neutralization effect of montelukast on SARS-CoV-2 is shown by multiscale in silico simulations and combined in vitro studies	95
High-dose systemic adeno-associated virus vector administration causes liver and sinusoidal endothelial cell injury	94
Generation of highly proliferative, rejuvenated cytotoxic T cell clones through pluripotency reprogramming for adoptive immunotherapy	93
Recombinant neutralizing secretory IgA antibodies for preventing mucosal acquisition and transmission of SARS-CoV-2	91
Targeting the central nervous system in lysosomal storage diseases: Strategies to deliver therapeutics across the blood-brain barrier	90
Antitumor activity of a lectibody targeting cancer-associated high-mannose glycans	86
Roles of lncRNAs in brain development and pathogenesis: Emerging therapeutic opportunities	84
How to democratize cell and gene therapy: A global approach	84
CRISPR-Cas9n-mediated ELANE promoter editing for gene therapy of severe congenital neutropenia	83
Lipid nanoparticle-mediated silencing of osteogenic suppressor GNAS leads to osteogenic differentiation of mesenchymal stem cells in vivo	80
Biologics-based technologies for highly efficient and targeted RNA delivery	80
AAV vector manufacturing process design and scalability - Bending the trajectory to address vector-associated immunotoxicities	79
MicroRNA-124-3p-enriched small extracellular vesicles as a therapeutic approach for Parkinson’s disease	79
Binding and neutralizing anti-AAV antibodies: Detection and implications for rAAV-mediated gene therapy	77
Late-Breaking Abstracts I	74
Gene editing efficiencies and hematopoietic stem cell fitness in sickle cell disease: A balancing act	74
In situ blockade of TNF-TNFR2 axis via oncolytic adenovirus improves antitumor efficacy in solid tumors	73
A promoterless AAV6.2FF-based lung gene editing platform for the correction of surfactant protein B deficiency	72
Systemic AAV9.BVES delivery ameliorates muscular dystrophy in a mouse model of LGMDR25	70
Targeting astrocytes with in vivo gene addition: Can it rescue loss of brain myelin?	69
Quo vadis American postdoc?	69
Single-cell transcriptomics unveil a unique molecular profile of mesenchymal stem/stromal cell-induced myeloid-derived immune suppressor cells	69
Fast, accurate ranking of engineered proteins by target-binding propensity using structure modeling	68
Efficient gene delivery admitted by small metabolites specifically targeting astrocytes in the mouse brain	68
Superantigen-fused T cell engagers for tumor antigen-mediated robust T cell activation and tumor cell killing	68
A minimally invasive endovascular approach to the cerebellopontine angle cistern enables broad CNS biodistribution of scAAV9-CB-GFP	68
T-cell specific in vivo gene delivery with DART-AAVs targeted to CD8	68
Myeloma cell-intrinsic ANXA1 elevation and T cell dysfunction contribute to BCMA-negative relapse after CAR-T therapy	67
Harnessing B19-directed CAR T cells for AAV vector administration in seropositive patients: The importance of the niche	67
Targeted long-read sequencing captures CRISPR editing and AAV integration outcomes in brain	65
Smoking and tetramer tryptase accelerate intervertebral disc degeneration by inducing METTL14-mediated DIXDC1 m6 modification	65
Long Noncoding RNA-Maternally Expressed Gene 3 Contributes to Hypoxic Pulmonary Hypertension	64